These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220 [TBL] [Abstract][Full Text] [Related]
29. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077 [TBL] [Abstract][Full Text] [Related]
30. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. Chen P; Zong L; Zhao W; Shi L World J Gastroenterol; 2010 Sep; 16(33):4227-32. PubMed ID: 20806443 [TBL] [Abstract][Full Text] [Related]
31. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202 [TBL] [Abstract][Full Text] [Related]
32. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors]. Zheng S; Jia J; Pan YL; Tao DY; Lu HS Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272 [No Abstract] [Full Text] [Related]
33. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905 [TBL] [Abstract][Full Text] [Related]
34. The GIST of targeted therapy for malignant melanoma. Bello DM; Dematteo RP; Ariyan CE Ann Surg Oncol; 2014 Jun; 21(6):2059-67. PubMed ID: 24531699 [TBL] [Abstract][Full Text] [Related]
36. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. Bickenbach K; Wilcox R; Veerapong J; Kindler HL; Posner MC; Noffsinger A; Roggin KK J Gastrointest Surg; 2007 Jun; 11(6):758-66. PubMed ID: 17417711 [TBL] [Abstract][Full Text] [Related]
37. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype. Judson IR J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449 [No Abstract] [Full Text] [Related]
38. [Consensus on the medical treatment of gastrointestinal stromal tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652 [No Abstract] [Full Text] [Related]
39. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case. Utsunomiya T; Okamoto M; Yano S; Kameyama T; Matsuyama A; Kuma S; Yamamoto M; Fujiwara M; Ishida T Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]